5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
May 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient education and personalized care.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
September 2023 in “Journal of the American Academy of Dermatology” May 2023 in “Journal of Drugs in Dermatology” REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
Medical Hair Restoration added a non-surgical hair therapy program to help people with early hair loss.
5 citations
,
June 2019 in “JAAD Case Reports” Imiquimod used intravaginally for cervical issues can cause temporary hair loss, especially if severe side effects occur.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.